Table 3 |
|||
|
Comparison of participants with and without ED |
|||
|
No erectile dysfunction (n = 23) |
Erectile dysfunction (n = 105) |
Odds ratio (95% confidence interval) |
|
|
|
|||
|
IIEF-5 score |
23 (22 to 25) |
11 (5 to 16) |
P < 0.001* |
|
Age (years)a |
45 (35.1 to 51.8) |
55.7 (47.1 to 62.9) |
P < 0.001* |
|
SSc duration by Raynaud's phenomenon (years) |
7.2 (4.3 to 15.3) |
7.0 (3.4 to 11.6) |
P = 0.44 |
|
SSc duration by first non-Raynaud's symptom (years) |
6.6 (4.3 to 11.8) |
5.6 (2.8 to 9.8) |
P = 0.41 |
|
Topoisomerase I (Scl70)-positive |
47.6 |
45.1 |
0.98 (0.80 to 1.19) |
|
ACA-positive |
5.0 |
18.8 |
1.21 (1.02 to 1.44)* |
|
U1RNP-positive |
0 |
5.9 |
1.25 (1.12 to 1.39)* |
|
RNA polymerase III-positive |
0 |
3.5 |
1.20 (1.08 to 1.33)* |
|
Diffuse SSc |
50 |
65.9 |
1.13 (0.92 to 1.40) |
|
Puffy hands |
57.1 |
52.9 |
0.97 (0.80 to 1.16) |
|
mRSS |
7 (2 to 19) |
14 (8 to 23) |
P = 0.05* |
|
mRSS > 20 |
15.8 |
26.8 |
1.13 (0.91 to 1.40) |
|
C-reactive protein elevation |
14.3 |
25.3 |
1.13 (0.93 to 1.37) |
|
Raynaud's phenomenon |
90.5 |
95.5 |
1.22 (0.69 to 2.17) |
|
Digital ulcers |
47.6 |
41.9 |
0.95 (0.79 to 1.16) |
|
Synovitis |
19.1 |
19.5 |
1.01 (0.80 to 1.27) |
|
Joint contractures |
19.1 |
33.3 |
1.14 (0.95 to 1.36) |
|
Tendon friction rubs |
4.8 |
10.3 |
1.13 (0.90 to 1.42) |
|
Muscle weakness |
9.5 |
20.7 |
1.15 (0.96 to 1.38) |
|
Muscle atrophy |
4.8 |
18.4 |
1.21 (1.03 to 1.42)* |
|
Creatine kinase elevation |
19.1 |
12.2 |
0.88 (0.62 to 1.25) |
|
Oesophageal symptoms |
57.1 |
59.1 |
1.02 (0.84 to 1.23) |
|
Stomach symptoms |
19.1 |
12.5 |
0.90 (0.65 to 1.23) |
|
Intestinal symptoms |
4.8 |
15.9 |
1.19 (0.99 to 1.41) |
|
Lung fibrosis on chest X-ray or HRCT |
42.9 |
56.9 |
1.13 (0.87 to 1.47) |
|
Forced vital capacity (% predicted) |
95 (87 to 107) |
91 (78 to 192) |
P = 0.52 |
|
Forced vital capacity < 80% |
9.5 |
25.7 |
1.26 (1.01 to 1.56)* |
|
DLCO (% predicted) |
81 (73 to 91) |
66 (53 to 82) |
P = 0.08 |
|
DLCO < 80% |
42.9 |
63.6 |
1.24 (0.95 to 1.61) |
|
PAPsys (mmHg) |
23.5 (0 to 28) |
29 (22 to 37) |
P = 0.04* |
|
PAPsys > 40 mmHg |
0 |
24.4 |
1.32 (1.17 to 1.50)* |
|
Diastolic dysfunction |
15.8 |
17.3 |
1.02 (0.79 to 1.33) |
|
Pericardial effusion |
5.6 |
4.4 |
0.95 (0.53 to 1.68) |
|
Left ventricular ejection fraction < 60% |
27.8 |
18.3 |
0.88 (0.65 to 1.20) |
|
Renal crisis |
0 |
4.6 |
1.25 (1.14 to 1.38)* |
|
Proteinuria |
19.1 |
6.0 |
0.68 (0.37 to 1.22) |
|
EULAR SSc activity score |
1.0 (0.5 to 2.0) |
2.5 (1.0 to 3.5) |
P = 0.02* |
|
High SSc activity (score ≥ 3) |
11.8 |
43.4 |
1.38 (1.09 to 1.75)* |
|
Hypocomplementaemia |
5.0 |
6.3 |
1.05 (0.72 to 1.52) |
|
|
|||
|
Data presented as median (interquartile range) or percentage unless indicated otherwise. DLCO, diffusion capacity of the lung for carbon monoxide; HRCT; IIEF-5, International Index of Erectile Function-5; mRSS; modified Rodnan skin score; PAPsys, systolic pulmonary arterial pressure; SSc, systemic sclerosis. aAge presented as mean + standard deviation (minimum to maximum). The star (*) denotes statistical significance |
|||
|
Foocharoen et al. Arthritis Research & Therapy 2012 14:R37 doi:10.1186/ar3748 |
|||
